Assessing the safety of luspatercept in Korean patients with myelodysplastic syndrome or beta thalassemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the real-world safety of luspatercept in adult Korean patients diagnosed with myelodysplastic syndrome (MDS) or beta thalassemia. Participants will be enrolled after starting treatment with luspatercept, and their safety outcomes will be monitored throughout the study. The study focuses on collecting data on adverse events and overall patient health in a real-world setting, providing insights into the drug's safety profile in this specific population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult participants 19 years of age or older
* Participants who will be treated with luspatercept according to the approved label in the Republic of Korea
* Participants who sign the informed consent form

Exclusion Criteria:

* Participants who are prescribed luspatercept for therapeutic indications not approved in the Republic of Korea
* Participants for whom luspatercept is contraindicated as clarified in the Korean prescribing information approved by the Ministry of Food and Drug Safety

Where it's running

• Novotech Laboratory Korea Co., Ltd.
  Seoul, South Korea Recruiting
• Local Institution - 0001
  Seoul, South Korea Terminated

Study contacts

• Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining Thalidomide with Danazol and Prednisolone for difficult beta-thalassemia in children

  This trial tests whether adding danazol and prednisolone to thalidomide helps children with transfusion-dependent beta-thalassemia who did not respond to thalidomide alone.

  Recruiting Phase 3 Khyber Medical University Peshawar · Peshawar, Khyber Pakhtunkhwa · NCT07884773

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Partial stem cell transplant for sickle cell disease and beta-thalassemia using matched donors

  This study tests a partial stem cell transplant from matched donors to help people with severe sickle cell disease or beta-thalassemia see if more donor cells can persist long-term.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07599176

• Total marrow and lymphoid irradiation with fludarabine and melphalan for older adults with refractory/relapsed AML or high-risk MDS undergoing donor stem cell transplant

  This phase 2 trial tests a targeted radiation conditioning (TMLI) with fludarabine and melphalan before a matched donor stem cell transplant in people aged 50 or older with difficult-to-treat AML or high-risk MDS.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07582172

• Nicotinamide Riboside and Pterostilbene in lower risk MDS and high-risk CCUS

  This phase 2 study tests whether nicotinamide riboside plus pterostilbene can help improve blood counts in adults with lower risk MDS or high-risk CCUS who are not transfusion-dependent.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT07579429

• QUAIL-100 in kids and young adults after stem cell transplant with high-risk blood cancers

  This study tests QUAIL-100 in pediatric and young adult patients who have high-risk acute leukemia or myelodysplastic syndrome and have already received a partially matched stem cell transplant.

  Recruiting Phase 1 Laguna Biotherapeutics, Inc. · Palo Alto, California · NCT07573111

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.